Rebecca A. Taub's Insider Trades & SAST Disclosures
Rebecca A. Taub's most recent trade in Madrigal Pharmaceuticals Inc was a trade of 7,381 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on March 5, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Rebecca A. Taub.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Madrigal Pharmaceuticals Inc | Rebecca A. Taub | Director, Pres., R&D, and CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Mar 2025 | 7,381 | 7,381 | - | - | Stock Option (Right to Buy) | |
| Madrigal Pharmaceuticals Inc | Rebecca A. Taub | Director, Pres., R&D, and CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Mar 2025 | 4,382 | 461,044 (2%) | 0% | 0 | Common Stock | |
| Madrigal Pharmaceuticals Inc | Rebecca A. Taub | Director, Pres., R&D, and CMO | Sale of securities on an exchange or to another person at price $ 335.24 per share. | 24 Jan 2025 | 648 | 456,662 (2%) | 0% | 335.2 | 217,236 | Common Stock |
| Madrigal Pharmaceuticals Inc | Rebecca A. Taub | Director, Pres., R&D, and CMO | Sale of securities on an exchange or to another person at price $ 273.41 per share. | 17 Jan 2025 | 1,689 | 457,310 (2%) | 0% | 273.4 | 461,789 | Common Stock |
| Madrigal Pharmaceuticals Inc | Rebecca A. Taub | Director, Pres., R&D, and CMO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.45 per share. | 08 Apr 2024 | 2,676 | 461,675 (2%) | 0% | 9.4 | 25,288 | Common Stock |
| Madrigal Pharmaceuticals Inc | Rebecca A. Taub | Director, Pres., R&D, and CMO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Apr 2024 | 2,676 | 76,564 | - | - | Stock Option (Right to Buy) | |
| Madrigal Pharmaceuticals Inc | Rebecca A. Taub | Director, Pres., R&D, and CMO | Sale of securities on an exchange or to another person at price $ 244.79 per share. | 08 Apr 2024 | 945 | 460,506 (2%) | 0% | 244.8 | 231,325 | Common Stock |
| Madrigal Pharmaceuticals Inc | Rebecca A. Taub | Director, Pres., R&D, and CMO | Sale of securities on an exchange or to another person at price $ 246.98 per share. | 08 Apr 2024 | 600 | 459,606 (2%) | 0% | 247.0 | 148,186 | Common Stock |
| Madrigal Pharmaceuticals Inc | Rebecca A. Taub | Director, Pres., R&D, and CMO | Sale of securities on an exchange or to another person at price $ 247.76 per share. | 08 Apr 2024 | 407 | 459,199 (2%) | 0% | 247.8 | 100,838 | Common Stock |
| Madrigal Pharmaceuticals Inc | Rebecca A. Taub | Director, Pres., R&D, and CMO | Sale of securities on an exchange or to another person at price $ 245.69 per share. | 08 Apr 2024 | 300 | 460,206 (2%) | 0% | 245.7 | 73,706 | Common Stock |
| Madrigal Pharmaceuticals Inc | Rebecca A. Taub | Director, Pres., R&D, and CMO | Sale of securities on an exchange or to another person at price $ 243.25 per share. | 08 Apr 2024 | 224 | 461,451 (2%) | 0% | 243.2 | 54,487 | Common Stock |
| Madrigal Pharmaceuticals Inc | Rebecca A. Taub | Director, Pres., R&D, and CMO | Sale of securities on an exchange or to another person at price $ 248.58 per share. | 08 Apr 2024 | 200 | 458,999 (2%) | 0% | 248.6 | 49,716 | Common Stock |
| Madrigal Pharmaceuticals Inc | Rebecca A. Taub | Director, Pres., R&D, and CMO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Apr 2024 | 27,845 | 125,283 | - | - | Stock Option (Right to Buy) | |
| Madrigal Pharmaceuticals Inc | Rebecca A. Taub | Director, Pres., R&D, and CMO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.45 per share. | 03 Apr 2024 | 27,845 | 486,844 (3%) | 0% | 9.4 | 263,135 | Common Stock |
| Madrigal Pharmaceuticals Inc | Rebecca A. Taub | Director, Pres., R&D, and CMO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Apr 2024 | 27,506 | 79,240 | - | - | Stock Option (Right to Buy) | |
| Madrigal Pharmaceuticals Inc | Rebecca A. Taub | Director, Pres., R&D, and CMO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.45 per share. | 03 Apr 2024 | 27,506 | 486,505 (3%) | 0% | 9.5 | 259,932 | Common Stock |
| Madrigal Pharmaceuticals Inc | Rebecca A. Taub | Director, Pres., R&D, and CMO | Sale of securities on an exchange or to another person at price $ 245.34 per share. | 03 Apr 2024 | 18,917 | 461,088 (2%) | 0% | 245.3 | 4,641,014 | Common Stock |
| Madrigal Pharmaceuticals Inc | Rebecca A. Taub | Director, Pres., R&D, and CMO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Apr 2024 | 18,537 | 106,746 | - | - | Stock Option (Right to Buy) | |
| Madrigal Pharmaceuticals Inc | Rebecca A. Taub | Director, Pres., R&D, and CMO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.45 per share. | 03 Apr 2024 | 18,537 | 477,536 (3%) | 0% | 9.5 | 175,175 | Common Stock |
| Madrigal Pharmaceuticals Inc | Rebecca A. Taub | Director, Pres., R&D, and CMO | Sale of securities on an exchange or to another person at price $ 243.33 per share. | 03 Apr 2024 | 8,989 | 466,356 (3%) | 0% | 243.3 | 2,187,288 | Common Stock |
| Madrigal Pharmaceuticals Inc | Rebecca A. Taub | Director, Pres., R&D, and CMO | Sale of securities on an exchange or to another person at price $ 242.61 per share. | 03 Apr 2024 | 8,817 | 475,345 (3%) | 0% | 242.6 | 2,139,069 | Common Stock |
| Madrigal Pharmaceuticals Inc | Rebecca A. Taub | Director, Pres., R&D, and CMO | Sale of securities on an exchange or to another person at price $ 241.85 per share. | 03 Apr 2024 | 5,619 | 467,717 (3%) | 0% | 241.9 | 1,358,971 | Common Stock |
| Madrigal Pharmaceuticals Inc | Rebecca A. Taub | Director, Pres., R&D, and CMO | Sale of securities on an exchange or to another person at price $ 245.53 per share. | 03 Apr 2024 | 5,278 | 458,999 (2%) | 0% | 245.5 | 1,295,924 | Common Stock |
| Madrigal Pharmaceuticals Inc | Rebecca A. Taub | Director, Pres., R&D, and CMO | Sale of securities on an exchange or to another person at price $ 240.88 per share. | 03 Apr 2024 | 4,200 | 473,336 (3%) | 0% | 240.9 | 1,011,679 | Common Stock |
| Madrigal Pharmaceuticals Inc | Rebecca A. Taub | Director, Pres., R&D, and CMO | Sale of securities on an exchange or to another person at price $ 244.68 per share. | 03 Apr 2024 | 4,070 | 480,005 (3%) | 0% | 244.7 | 995,854 | Common Stock |
| Madrigal Pharmaceuticals Inc | Rebecca A. Taub | Director, Pres., R&D, and CMO | Sale of securities on an exchange or to another person at price $ 242.71 per share. | 03 Apr 2024 | 3,085 | 464,632 (3%) | 0% | 242.7 | 748,765 | Common Stock |
| Madrigal Pharmaceuticals Inc | Rebecca A. Taub | Director, Pres., R&D, and CMO | Sale of securities on an exchange or to another person at price $ 245.06 per share. | 03 Apr 2024 | 2,734 | 461,463 (2%) | 0% | 245.1 | 670,006 | Common Stock |
| Madrigal Pharmaceuticals Inc | Rebecca A. Taub | Director, Pres., R&D, and CMO | Sale of securities on an exchange or to another person at price $ 243.68 per share. | 03 Apr 2024 | 2,634 | 484,075 (3%) | 0% | 243.7 | 641,866 | Common Stock |
| Madrigal Pharmaceuticals Inc | Rebecca A. Taub | Director, Pres., R&D, and CMO | Sale of securities on an exchange or to another person at price $ 246.33 per share. | 03 Apr 2024 | 2,089 | 458,999 (2%) | 0% | 246.3 | 514,573 | Common Stock |
| Madrigal Pharmaceuticals Inc | Rebecca A. Taub | Director, Pres., R&D, and CMO | Sale of securities on an exchange or to another person at price $ 244.45 per share. | 03 Apr 2024 | 2,079 | 464,277 (3%) | 0% | 244.5 | 508,213 | Common Stock |
| Madrigal Pharmaceuticals Inc | Rebecca A. Taub | Director, Pres., R&D, and CMO | Sale of securities on an exchange or to another person at price $ 246.01 per share. | 03 Apr 2024 | 1,653 | 459,810 (2%) | 0% | 246.0 | 406,658 | Common Stock |
| Madrigal Pharmaceuticals Inc | Rebecca A. Taub | Director, Pres., R&D, and CMO | Sale of securities on an exchange or to another person at price $ 240.11 per share. | 03 Apr 2024 | 1,643 | 484,862 (3%) | 0% | 240.1 | 394,497 | Common Stock |
| Madrigal Pharmaceuticals Inc | Rebecca A. Taub | Director, Pres., R&D, and CMO | Sale of securities on an exchange or to another person at price $ 247.23 per share. | 03 Apr 2024 | 711 | 459,099 (2%) | 0% | 247.2 | 175,778 | Common Stock |
| Madrigal Pharmaceuticals Inc | Rebecca A. Taub | Director, Pres., R&D, and CMO | Sale of securities on an exchange or to another person at price $ 241.14 per share. | 03 Apr 2024 | 700 | 484,162 (3%) | 0% | 241.1 | 168,799 | Common Stock |
| Madrigal Pharmaceuticals Inc | Rebecca A. Taub | Director, Pres., R&D, and CMO | Sale of securities on an exchange or to another person at price $ 244.01 per share. | 03 Apr 2024 | 435 | 464,197 (3%) | 0% | 244.0 | 106,143 | Common Stock |
| Madrigal Pharmaceuticals Inc | Rebecca A. Taub | Director, Pres., R&D, and CMO | Sale of securities on an exchange or to another person at price $ 242.00 per share. | 03 Apr 2024 | 135 | 486,709 (3%) | 0% | 242 | 32,670 | Common Stock |
| Madrigal Pharmaceuticals Inc | Rebecca A. Taub | Director, Pres., R&D, and CMO | Sale of securities on an exchange or to another person at price $ 248.23 per share. | 03 Apr 2024 | 100 | 458,999 (2%) | 0% | 248.2 | 24,823 | Common Stock |
| Madrigal Pharmaceuticals Inc | Taub Rebecca A. | Director, Pres., R&D, and CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2024 | 8,718 | 8,718 | - | - | Stock Option (Right to Buy) | |
| Madrigal Pharmaceuticals Inc | Rebecca Taub A. | Director, Pres., R&D, and CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2024 | 5,786 | 5,786 | - | - | Market Stock Unit | |
| Madrigal Pharmaceuticals Inc | Rebecca Taub A. | Director, Pres., R&D, and CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2024 | 5,786 | 20,787 (0%) | 0% | 0 | Common Stock | |
| Madrigal Pharmaceuticals Inc | Rebecca Taub A. | Director, Pres., R&D, and CMO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 243.92 per share. | 16 Jan 2024 | 1,546 | 15,001 (0%) | 0% | 243.9 | 377,100 | Common Stock |
| Madrigal Pharmaceuticals Inc | Rebecca A. Taub | Director, Pres., R&D, and CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jan 2023 | 20,001 | 20,001 (0%) | 0% | 0 | Common Stock | |
| Madrigal Pharmaceuticals Inc | Rebecca A. Taub | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2022 | 61,500 | 61,500 | - | - | Stock Option (Right to Buy) | |
| Madrigal Pharmaceuticals Inc | Rebecca A. Taub | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2021 | 44,000 | 44,000 | - | - | Stock Option (Right to Buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges